Immutep rises as combination therapy shows results in lung cancer trial
24/05/2023 16:11
** U.S.-listed shares of Australia-based biotech Immutep Ltd
IMMP.O IMMP.BLUE rise 15.7% to $2.66
** Co says triple combination therapy remains well-tolerated
and shows initial efficacy signals in early stage trial
** Data shows that combination therapy shows 67% overall
response rate and 91% disease control rate in patients with a
type of lung cancer
** The trial is evaluating a triple combination therapy of
co's efti with approved standard-of-care combination of Merck's
MRK.N keytruda and chemotherapy in first line non-small cell
lung cancer
** U.S.-listed stock of the company up ~53% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))